Ritter Pharmaceuticals has partnered with the University of British Columbia (UBC)’s Michael Smith Laboratories in Canada to explore development of microbiome and RP-G28 in environmental enteropathy (EE).

As part of the collaboration, Ritter is providing its lead compound RP-G28 for use in the study and UBC microbiologist Dr B Brett Finlay will explore the microbiome’s role in EE. 

The latest pre-clinical research has been designed to build upon Dr Finlay’s studies that were previously published, demonstrating the gut microbiome’s role in contributing to the causes of EE. 

Ritter Pharmaceuticals co-founder and president Andrew Ritter said: “We are pleased to be collaborating with Dr Finlay and his team to better understand therapeutic interventions that may reverse signs of environmental enteropathy, a significant worldwide health issue. 

"Testing RP-G28 in the relevant model will greatly facilitate preclinical testing of this compound for affecting the outcome of EE."

“We’re excited to apply our clinical knowledge of RP-G28 in a way that has significant possibilities to produce substantial social benefits in developing countries.”

At present, RP-G28 is in a Phase IIb/3 study in humans for the treatment of lactose intolerance and has demonstrated beneficial changes to the gut microbiome in earlier studies.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Dr Finlay said: “We are pleased to be working with Ritter Pharmaceuticals to explore potential treatments and therapies to environmental enteropathy that affects so many of the world’s children. 

“Testing RP-G28 in the relevant model will greatly facilitate preclinical testing of this compound for affecting the outcome of EE.”

Ritter’s RP-G28 has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects people worldwide.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now